person · Reporting owner
Butera Salvatore Thomas
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VOLITIONRX LTDVNRX · Entity 8241 | CEO - Volition Veterinary | January 22, 2026 | January 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VOLITIONRX LTD
Report date January 22, 2026 · Filed January 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 375,203 |
Reported balance
After 2026-01-22 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2026-01-22 · Grant · Acquired 53,400 · Balance 375,203 F1: On March 17, 2025, the reporting person was awarded 178,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to June 30, 2025 and December 31, 2025 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 53,400 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 17,800 units on each of March 17, 2026, 2027 and 2028, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. The rights with respect to the remaining 124,600 RSUs did not vest and were cancelled on June 30, 2025 and January 22, 2026, respectively. |
| Common StockSEC Table I · non-derivative | Direct | 99,350 |
Reported balance
Holding disclosure · report date 2026-01-22 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 99,350 F2: These shares of common stock are jointly owned by the reporting person and his spouse. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 17, 2025, the reporting person was awarded 178,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to June 30, 2025 and December 31, 2025 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 53,400 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 17,800 units on each of March 17, 2026, 2027 and 2028, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. The rights with respect to the remaining 124,600 RSUs did not vest and were cancelled on June 30, 2025 and January 22, 2026, respectively.
F2: These shares of common stock are jointly owned by the reporting person and his spouse.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 22, 2026 Filed Jan 23, 2026 21:06 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 53,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-26-000364 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,203 F1 · shares: On March 17, 2025, the reporting person was awarded 178,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to June 30, 2025 and December 31, 2025 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 53,400 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 17,800 units on each of March 17, 2026, 2027 and 2028, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. The rights with respect to the remaining 124,600 RSUs did not vest and were cancelled on June 30, 2025 and January 22, 2026, respectively. Read SEC document |
| November 01, 2025 Filed Nov 4, 2025 21:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Tax withholdingCommon Stock | 4,648 | $0.43 | $2,017.23 |
DisclosureSEC source: 0001477932-25-007899 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 321,803 F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 16,996 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction. Read SEC document |
| October 04, 2025 Filed Oct 7, 2025 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Tax withholdingCommon Stock | 5,834 | $0.65 | $3,780.43 |
DisclosureSEC source: 0001477932-25-007405 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 326,451 F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 21,333 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction. Read SEC document |
| September 28, 2025 Filed Sep 30, 2025 20:02 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Tax withholdingCommon Stock | 5,230 | $0.61 | $3,164.15 |
DisclosureSEC source: 0001477932-25-007232 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 332,285 F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 19,125 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:06 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 33,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-25-006100 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 337,515 F1 · shares: On August 15, 2025, the reporting person was awarded 33,991 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in six approximately equal monthly installments commencing on September 1, 2025. Once earned, they will remain subject to additional time-based vesting in two installments of 16,996 units and 16,995 units on each of November 1, 2025 and February 1, 2026, respectively, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the applicable vesting date. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 20:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Tax withholdingCommon Stock | 6,393 | $0.64 | $4,091.52 |
DisclosureSEC source: 0001477932-25-005474 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 303,524 F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 23,377 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 17:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Tax withholdingCommon Stock | 4,462 | $0.77 | $3,426.37 |
DisclosureSEC source: 0001477932-25-004913 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 309,917 F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 16,871 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:06 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Tax withholdingCommon Stock | 11,683 | $0.50 | $5,876.55 |
DisclosureSEC source: 0001477932-25-004371 · form4.xml · nonDerivative · entry 2 Butera Salvatore Thomas · CIK 0001834339 · CEO, Volition Veterinary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 314,379 F2 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 35,783 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:06 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 23,377 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-25-004371 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO, Volition Veterinary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 326,062 F1 · shares: On June 1, 2025, the reporting person was awarded 23,377 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 7,793 units, 7,792 units, and 7,792 units on each of June 1, 2025, July 1, 2025 and August 1, 2025, respectively, are also subject to further time-based vesting in a single installment on August 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Tax withholdingCommon Stock | 10,205 | $0.49 | $4,974.94 |
DisclosureSEC source: 0001477932-25-003317 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO, Volition Veterinary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 302,685 F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 31,256 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 19,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-25-001458 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 312,890 F1 · shares: On March 1, 2025, the reporting person was awarded 19,300 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 6,434 units, 6,433 units, and 6,433 units on each of March 1, 2025, April 1, 2025 and May 1, 2025, respectively, are also subject to further time-based vesting in a single installment on March 1, 2026, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| December 01, 2024 Filed Dec 3, 2024 21:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 16,871 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-007799 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO, Volition Veterinary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 293,590 F1 · shares: On December 1, 2024, the reporting person was awarded 16,871 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 5,624 units, 5,624 units, and 5,623 units on each of December 1, 2024, January 1, 2025 and February 1, 2025, respectively, are also subject to further time-based vesting in a single installment on July 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| October 04, 2024 Filed Oct 8, 2024 20:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Tax withholdingCommon Stock | 5,834 | $0.88 | $5,151.42 |
DisclosureSEC source: 0001477932-24-006286 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO, Volition Veterinary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 276,719 F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 21,333 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction. Read SEC document |
| September 28, 2024 Filed Oct 1, 2024 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Tax withholdingCommon Stock | 5,230 | $0.58 | $3,022.94 |
DisclosureSEC source: 0001477932-24-006098 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO Volition Veterinary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 282,553 F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 19,125 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction. Read SEC document |
| September 01, 2024 Filed Sep 4, 2024 20:02 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 35,783 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-005497 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 287,783 F1 · shares: On September 1, 2024, the reporting person was awarded 35,783 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 11,928 units, 11,928 units, and 11,927 units on each of September 1, 2024, October 1, 2024 and November 1, 2024, respectively, are also subject to further time-based vesting in a single installment on June 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| August 15, 2024 Filed Aug 16, 2024 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 21,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-005026 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO, Volition Veterinary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 252,000 F1 · shares: On Sept 28, 2023, the reporting person was awarded 85,000 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to Dec 31, 2023 and June 30, 2024 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 21,250 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three installments of 7,083 units, 7,083 units, and 7,084 units on each of Sept 28, 2024, 2025 and 2026, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. As reported in Jan 2024, the rights with respect to 36,125 RSUs subject to the award previously vested and remain subject to time-based vesting. The rights with respect to the remaining 27,625 RSUs did not vest and were cancelled on August 15, 2024. Read SEC document |
| June 01, 2024 Filed Jun 4, 2024 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 31,256 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-003480 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,750 F1 · shares: On June 1, 2024, the reporting person was awarded 31,256 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 10,419 units, 10,419 units, and 10,418 units on each of June 1, 2024, July 1, 2024 and August 1, 2024, respectively, are also subject to further time-based vesting in a single installment on May 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:07 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Tax withholdingCommon Stock | 15,504 | $0.87 | $13,488.48 |
DisclosureSEC source: 0001477932-24-002515 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO, Volition Veterinary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,494 F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 50,000 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 21:02 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 36,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-000405 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,998 F1 · shares: On September 28, 2023, the reporting person was awarded 85,000 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2023 and June 30, 2024 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 36,125 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three installments of 12,042 units, 12,042 units, and 12,041 units on each of September 28, 2024, September 28, 2025 and September 28, 2026, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| December 18, 2023 Filed Dec 19, 2023 15:59 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 10,000 | $0.83 | $8,300.00 |
DisclosureSEC source: 0001477932-23-009233 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,350 F1 · ownership.direct: These shares of common stock are jointly owned by the reporting person and his spouse. Read SEC document |
| December 15, 2023 Filed Dec 18, 2023 14:38 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 10,000 | $0.77 | $7,700.00 |
DisclosureSEC source: 0001477932-23-009191 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,350 F1 · ownership.direct: These shares of common stock are jointly owned by the reporting person and his spouse. Read SEC document |
| November 16, 2023 Filed Nov 17, 2023 15:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 10,000 | $0.81 | $8,100.00 |
DisclosureSEC source: 0001477932-23-008596 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,350 F1 · ownership.direct: These shares of common stock are jointly owned by the reporting person and his spouse. Read SEC document |
| October 04, 2023 Filed Oct 6, 2023 20:06 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Tax withholdingCommon Stock | 5,834 | $0.68 | $3,937.95 |
DisclosureSEC source: 0001477932-23-007443 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,873 F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 21,334 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction. Read SEC document |
| August 16, 2023 Filed Aug 17, 2023 13:40 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 8,000 | $1.21 | $9,680.00 |
DisclosureSEC source: 0001477932-23-006234 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,350 F1 · ownership.direct: These shares of common stock are jointly owned by the reporting person and his spouse. Read SEC document |
| July 05, 2023 Filed Jul 7, 2023 20:02 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 28,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-005118 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,707 F1 · shares: On October 4, 2022, the reporting person was awarded 64,000 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 28,800 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 9,600 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. As reported in October 2022 and January 2023 respectively, the rights with respect to 11,200 RSUs and 24,000 RSUs subject to the award previously vested and remain subject to time-based vesting. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 14:14 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 10,000 | $1.59 | $15,900.00 |
DisclosureSEC source: 0001477932-23-004251 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,350 F1 · ownership.direct: These shares of common stock are jointly owned by the reporting person and his spouse. Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:20 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Tax withholdingCommon Stock | 14,293 | $1.67 | $23,869.31 |
DisclosureSEC source: 0001477932-23-003072 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,907 F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 50,000 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction. Read SEC document |
| January 12, 2023 Filed Jan 13, 2023 21:04 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-000277 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,200 F1 · shares: On October 4, 2022, the reporting person was awarded 64,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 24,000 restricted stock units vesting. The restricted stock units are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 8,000 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in October 2022, the rights with respect to 11,200 restricted stock units subject to the award previously vested and remain subject to time-based vesting. Read SEC document |
| December 19, 2022 Filed Dec 20, 2022 15:30 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 5,000 | $2.27 | $11,350.00 |
DisclosureSEC source: 0001477932-22-009425 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,350 F1 · ownership.direct: These shares of common stock are jointly owned by the reporting person and his spouse. Read SEC document |
| December 12, 2022 Filed Dec 13, 2022 14:59 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 4,350 | $2.09 | $9,091.50 |
DisclosureSEC source: 0001477932-22-009249 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,350 F1 · ownership.direct: These shares of common stock are jointly owned by the reporting person and his spouse. Read SEC document |
| November 28, 2022 Filed Nov 29, 2022 15:57 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 5,000 | $2.21 | $11,050.00 |
DisclosureSEC source: 0001477932-22-008934 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 F1 · ownership.direct: These shares of common stock are jointly owned by the reporting person and his spouse. Read SEC document |
| October 13, 2022 Filed Oct 14, 2022 20:07 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 11,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-007701 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,200 F1 · shares: On October 4, 2022, the reporting person was awarded 64,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 11,200 restricted stock units vesting. The restricted stock units are further subject to a 3-year time-based vesting schedule, vesting in three installments of 3,734 units, 3,733 units, and 3,733 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| August 23, 2022 Filed Aug 24, 2022 14:52 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 5,000 | $1.60 | $8,000.00 |
DisclosureSEC source: 0001477932-22-006435 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Read SEC document |
| August 22, 2022 Filed Aug 23, 2022 15:14 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 5,000 | $1.64 | $8,200.00 |
DisclosureSEC source: 0001477932-22-006406 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 34,060 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001477932-22-004667 · form4.xml · derivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,400 Underlying: Common Stock · 34,060 shares Expires 2031-08-03 F1 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 52,400 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 34,060 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 17,030 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 18,340 shares subject to the award previously vested and remain subject to time-based vesting. F1 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 52,400 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 34,060 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 17,030 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 18,340 shares subject to the award previously vested and remain subject to time-based vesting. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 10,000 | $2.05 | $20,500.00 |
DisclosureSEC source: 0001477932-22-004498 · form4.xml · nonDerivative · entry 2 Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,000 Read SEC document |
| May 01, 2022 Filed Jun 17, 2022 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Tax withholdingCommon Stock | 15,000 | $2.79 | $41,850.00 |
DisclosureSEC source: 0001477932-22-004498 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 50,000 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction. Read SEC document |
| April 07, 2022 Filed Apr 8, 2022 20:03 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 18,340 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001477932-22-002180 · form4.xml · derivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,340 Underlying: Common Stock · 18,340 shares Expires 2031-08-03 F1 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 52,400 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 18,340 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 9,170 shares on each of August 3, 2022 and August 3, 2023, respectively. F1 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 52,400 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 18,340 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 9,170 shares on each of August 3, 2022 and August 3, 2023, respectively. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 15:39 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 10,000 | $4.02 | $40,200.00 |
DisclosureSEC source: 0001477932-21-008524 · form4.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO-Volition Veterinary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| May 01, 2021 Filed May 4, 2021 20:27 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001078782-21-000416 · primary_doc.xml · nonDerivative · entry 2 Butera Salvatore Thomas · CIK 0001834339 · CEO-Volition Veterinary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 F2 · shares: In connection with his employment as Chief Executive Officer of Volition Veterinary Diagnostics Development, LLC, Dr. Butera received restricted stock units subject to a 3-year vesting schedule, vesting as to 50,000 units on each of 05/01/22, 05/01/23 and 05/01/24, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| March 25, 2021 Filed May 4, 2021 20:27 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Disposition to issuerCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001078782-21-000416 · primary_doc.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · CEO-Volition Veterinary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: The reported transaction involved a cancellation of unvested restricted stock units upon Dr. Butera's resignation as a director of the issuer. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:42 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001078782-20-000946 · primary_doc.xml · nonDerivative · entry 1 Butera Salvatore Thomas · CIK 0001834339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Dr. Butera received restricted stock units subject to a 2-year vesting schedule, vesting as to 7,500 units on each of 12/01/21 and 12/01/22, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.